Alpha Tau Medical Ltd DRTS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DRTS is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.41
- Day Range
- $2.41–2.47
- 52-Week Range
- $2.38–4.80
- Bid/Ask
- $2.46 / $2.56
- Market Cap
- $172.09 Mil
- Volume/Avg
- 56 / 34,513
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation’s range.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 121
- Website
- https://www.alphatau.com
Comparables
Valuation
|
Metric
|
DRTS
|
NYKD
|
YMAB
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.06 | 2.51 | 6.58 |
Price/Sales | — | 29.40 | 7.83 |
Price/Cash Flow | — | — | — |
Price/Earnings
DRTS
NYKD
YMAB
Financial Strength
|
Metric
|
DRTS
|
NYKD
|
YMAB
|
|---|---|---|---|
Quick Ratio | 11.56 | 7.91 | 5.02 |
Current Ratio | 12.07 | 8.04 | 5.52 |
Interest Coverage | −451.95 | −235.75 | — |
Quick Ratio
DRTS
NYKD
YMAB
Profitability
|
Metric
|
DRTS
|
NYKD
|
YMAB
|
|---|---|---|---|
Return on Assets (Normalized) | −21.92% | −19.18% | −8.24% |
Return on Equity (Normalized) | −26.10% | −26.31% | −10.52% |
Return on Invested Capital (Normalized) | −27.78% | −30.96% | −13.95% |
Return on Assets
DRTS
NYKD
YMAB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ftgmcdfgkp | Xbsn | $578.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lsgpzhnbw | Hgwshtn | $101.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qjsvgscw | Cykpp | $98.1 Bil | |
MRNA
| Moderna Inc | Rxqmbcps | Mgr | $42.2 Bil | |
ARGX
| argenx SE ADR | Xqnhpyzbv | Ykfxt | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qwlknnp | Plkc | $21.4 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Srkmkgqn | Hnlvqc | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Msnkzwqf | Zwgpt | $15.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Sdtpdbhs | Rngkv | $12.5 Bil | |
INCY
| Incyte Corp | Brcjxkn | Phjml | $11.7 Bil |